prostate cancer

New products: Holmium laser increases stone ablation volumeOther products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Higher reclassification rate seen with saturation biopsyTransrectal saturation biopsy resulted in higher rates of disease reclassification compared with magnetic resonance (MR) fusion biopsy plus extended sextant prostate biopsy in patients with low-risk prostate cancer on active surveillance.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drugOther pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
BMI predicts post-RP metastasis, PCa mortalityFindings from a recent study also suggest that obesity may be a factor to consider for men with prostate cancer deciding between active surveillance and definitive treatment.
Pre-RP MRI does not affect surgical outcomesResults of a retrospective case-cohort study show no significant differences in surgical outcomes among men who did and did not have preoperative magnetic resonance imaging of the prostate prior to radical prostatectomy for prostate cancer.
Bx-related complications influence decision-making
Bx-related complications influence decision-makingMen who experience a prostate biopsy-related complication are more likely to seek active treatment for clinically localized prostate cancer than those who do not experience a complication, according to findings from a review of the Surveillance, Epidemiology, and End Results Medicare linked database.
Prostate MRI: Value in surgical planning?
AUA issues recommendations on surveillance, opioidsContinuing its participation in the Choosing Wisely campaign, the AUA has added five new recommendations about tests and treatments that physicians and patients should question.
Dear USPSTF: Don’t discount value of PSA in men 70+“We strongly believe that PSA-based prostate cancer screening should be made available, especially to men 70 years and older to decrease the morbidity and mortality of prostate cancer,” write Navin Shah, MD, and Vladimir Ioffe, MD.
Metastatic PCa: Studies point to new standard of care“Abiraterone should change the treatment paradigm for patients with newly diagnosed metastatic prostate cancer and largely displaces chemotherapy from the current paradigm,” said Sumanta Kumar Pal, MD.